220 related articles for article (PubMed ID: 23838182)
1. Blockade of glioma proliferation through allosteric inhibition of JAK2.
He K; Qi Q; Chan CB; Xiao G; Liu X; Tucker-Burden C; Wang L; Mao H; Lu X; McDonald FE; Luo H; Fan QW; Weiss WA; Sun SY; Brat DJ; Ye K
Sci Signal; 2013 Jul; 6(283):ra55. PubMed ID: 23838182
[TBL] [Abstract][Full Text] [Related]
2. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
[TBL] [Abstract][Full Text] [Related]
3. 15-Lipoxygenase-1-enhanced Src-Janus kinase 2-signal transducer and activator of transcription 3 stimulation and monocyte chemoattractant protein-1 expression require redox-sensitive activation of epidermal growth factor receptor in vascular wall remodeling.
Singh NK; Wang D; Kundumani-Sridharan V; Van Quyen D; Niu J; Rao GN
J Biol Chem; 2011 Jun; 286(25):22478-88. PubMed ID: 21536676
[TBL] [Abstract][Full Text] [Related]
4. Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.
Premkumar DR; Jane EP; Pollack IF
Cancer Biol Ther; 2015; 16(2):233-43. PubMed ID: 25482928
[TBL] [Abstract][Full Text] [Related]
5. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
[TBL] [Abstract][Full Text] [Related]
6. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.
Yiin JJ; Hu B; Schornack PA; Sengar RS; Liu KW; Feng H; Lieberman FS; Chiou SH; Sarkaria JN; Wiener EC; Ma HI; Cheng SY
Mol Cancer Ther; 2010 Apr; 9(4):929-41. PubMed ID: 20371720
[TBL] [Abstract][Full Text] [Related]
7. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
8. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
Wang MY; Lu KV; Zhu S; Dia EQ; Vivanco I; Shackleford GM; Cavenee WK; Mellinghoff IK; Cloughesy TF; Sawyers CL; Mischel PS
Cancer Res; 2006 Aug; 66(16):7864-9. PubMed ID: 16912159
[TBL] [Abstract][Full Text] [Related]
9. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
Gini B; Zanca C; Guo D; Matsutani T; Masui K; Ikegami S; Yang H; Nathanson D; Villa GR; Shackelford D; Zhu S; Tanaka K; Babic I; Akhavan D; Lin K; Assuncao A; Gu Y; Bonetti B; Mortensen DS; Xu S; Raymon HK; Cavenee WK; Furnari FB; James CD; Kroemer G; Heath JR; Hege K; Chopra R; Cloughesy TF; Mischel PS
Clin Cancer Res; 2013 Oct; 19(20):5722-32. PubMed ID: 24030701
[TBL] [Abstract][Full Text] [Related]
10. The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.
Baskin R; Park SO; Keserű GM; Bisht KS; Wamsley HL; Sayeski PP
PLoS One; 2014; 9(8):e105568. PubMed ID: 25162558
[TBL] [Abstract][Full Text] [Related]
11. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
[TBL] [Abstract][Full Text] [Related]
12. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
[TBL] [Abstract][Full Text] [Related]
13. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
Fenton TR; Nathanson D; Ponte de Albuquerque C; Kuga D; Iwanami A; Dang J; Yang H; Tanaka K; Oba-Shinjo SM; Uno M; Inda MM; Wykosky J; Bachoo RM; James CD; DePinho RA; Vandenberg SR; Zhou H; Marie SK; Mischel PS; Cavenee WK; Furnari FB
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14164-9. PubMed ID: 22891331
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of the pro-inflammatory biomarker, YKL-40/CHI3L1, by PTEN/Phosphoinositide 3-kinase and JAK2/STAT3 pathways in glioblastoma.
Wang Y; Wong CW; Yan M; Li L; Liu T; Or PM; Tsui SK; Waye MM; Chan AM
Cancer Lett; 2018 Aug; 429():54-65. PubMed ID: 29729901
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes.
Lo HW; Cao X; Zhu H; Ali-Osman F
Mol Cancer Res; 2010 Feb; 8(2):232-45. PubMed ID: 20145033
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
Rong Y; Belozerov VE; Tucker-Burden C; Chen G; Durden DL; Olson JJ; Van Meir EG; Mackman N; Brat DJ
Cancer Res; 2009 Mar; 69(6):2540-9. PubMed ID: 19276385
[TBL] [Abstract][Full Text] [Related]
17. Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.
Balanis N; Wendt MK; Schiemann BJ; Wang Z; Schiemann WP; Carlin CR
J Biol Chem; 2013 Jun; 288(25):17954-67. PubMed ID: 23653350
[TBL] [Abstract][Full Text] [Related]
18. The VHL tumor suppressor protein regulates tumorigenicity of U87-derived glioma stem-like cells by inhibiting the JAK/STAT signaling pathway.
Kanno H; Sato H; Yokoyama TA; Yoshizumi T; Yamada S
Int J Oncol; 2013 Mar; 42(3):881-6. PubMed ID: 23338840
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells.
Senft C; Priester M; Polacin M; Schröder K; Seifert V; Kögel D; Weissenberger J
J Neurooncol; 2011 Feb; 101(3):393-403. PubMed ID: 20589525
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-146a inhibits glioma development by targeting Notch1.
Mei J; Bachoo R; Zhang CL
Mol Cell Biol; 2011 Sep; 31(17):3584-92. PubMed ID: 21730286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
